Explorer›Medicine›Open Science
Research PaperResearchia:202603.30053

Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial

Carlos Brites

Abstract

Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial --- Source: OpenAlex - Clinical Infectious Diseases (Citations: 1) PDF: N/A Original Link: https://doi.org/https://doi.org/10.1093/cid/ciag163

Submitted: March 30, 2026Subjects: Open Science; Medicine

Description / Details

Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial

Source: OpenAlex - Clinical Infectious Diseases (Citations: 1) PDF: N/A Original Link: https://doi.org/https://doi.org/10.1093/cid/ciag163

Please sign in to join the discussion.

No comments yet. Be the first to share your thoughts!

Access Paper
Submission Info
Date:
Mar 30, 2026
Topic:
Medicine
Area:
Open Science
Comments:
0
Bookmark